European Parliament Proposes Reforms to Legislation Around Pharmaceutical Data Exclusivity The European pharmaceutical industry is facing a range of challenges, including unequal access to medicines across member states, high prices for innovative treatments, shortages of essential medicines, and the steady decline of the EU’s share of R&D funding for new medicines between 2001 and 2020. In response, the European Parliament has proposed reforms to regulatory exclusivities. This Policy Brief explores the problem, proposed reforms, and lessons learned